Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology
  • Published:

Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families

Abstract

To estimate the prevalence of TP53 mutations in familial breast cancer, constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations. Genomic DNA from 128 breast cancer patients belonging to 109 families with familial cancer were screened. No germline mutations were found in any of the patients. We also studied TP53 mutations in tumour DNA from 51 of the same individuals and found mutations in 14%. This is similar to what has been reported in sporadic breast cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zelada-Hedman, M., Børresen-Dale, AL., Claro, A. et al. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 75, 1201–1204 (1997). https://doi.org/10.1038/bjc.1997.205

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1997.205

This article is cited by

Search

Quick links